drugset / Trial / NCT01552707
Safety Study of Mesenchymal Stem Cells and Spinal Fusion
Phase 1/2
Completed
69 enrolled
Blood and Tissue Bank of Catalonia
Ministerio de Ciencia e Innovación, Spain · collabMinisterio de Sanidad, Servicios Sociales e Igualdad · collabTFS Trial Form Support · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The present prospective, randomized study, compares the spinal fusion obtained after instrumentation and the use of a biologic product (patient's mesenchymal cells obtained from his/her own bone marrow which will be fixed in human bone tissue form a donor), with the current procedure that consists in instrumented spinal fusion and the use of each patient's bone obtained from his/her iliac crest. The working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the need for obtaining patient's iliac crest and its associated morbidity.
Timeline
- Start
- 2012-07-19
- Primary completion
- 2018-05-03
- Completion
- 2019-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XCEL-MT-OSTEO-ALPHA | Cell therapy | — | — |